Poly (ADP-ribose) polymerase (PARP) inhibitors are novel class of drugs developed to treat BRCA gene related cancers. It works by blocking the action of PARP enzyme that helps DNA repair mechanism. Without this repair DNA damage accumulates in cancer cells leading to their death. The global PARP Inhibitor Market is estimated to be valued at US$ 6.13 Bn in 2023 and is expected to exhibit a CAGR of 6.8% over the forecast period 2023 to 2030, ... Read more
